ID   LR-SKBR3
AC   CVCL_A2GI
DR   cancercelllines; CVCL_A2GI
DR   Wikidata; Q105509950
RX   PubMed=32942617;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:49603; Lapatinib (Tykerb; Tyverb).
CC   Sequence variation: Gene deletion; HGNC; 1748; CDH1; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg175His (c.524G>A); ClinVar=VCV000012374; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C5214; Breast adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0033 ! SK-BR-3
SX   Female
AG   43Y
CA   Cancer cell line
DT   Created: 12-01-21; Last updated: 05-10-23; Version: 5
//
RX   PubMed=32942617; DOI=10.3390/cancers12092630;
RA   Lee H.J., Shin S., Kang J., Han K.-C., Kim Y.H., Bae J.-W., Park K.H.;
RT   "HSP90 inhibitor, 17-DMAG, alone and in combination with lapatinib
RT   attenuates acquired lapatinib-resistance in ER-positive,
RT   HER2-overexpressing breast cancer cell line.";
RL   Cancers (Basel) 12:2630.1-2630.16(2020).
//